{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:41:03Z","timestamp":1787161263301,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-025-12431-3","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T02:23:51Z","timestamp":1740795831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7096-5276","authenticated-orcid":false,"given":"Zahra","family":"Goudarzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0258-8015","authenticated-orcid":false,"given":"Zhila","family":"Najafpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1851-159X","authenticated-orcid":false,"given":"Ahmad","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-5502","authenticated-orcid":false,"given":"Khosro","family":"Keshavarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-2195","authenticated-orcid":false,"given":"Mohammad Mahdi","family":"Mojahedian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mehdi","family":"Babayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"issue":"11","key":"12431_CR1","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3390\/nu10111724","volume":"10","author":"PF Tsui","year":"2018","unstructured":"Tsui PF, Lin CS, Ho LJ, Lai JH. Spices and atherosclerosis. Nutrients. 2018;10(11):1724.","journal-title":"Nutrients"},{"key":"12431_CR2","doi-asserted-by":"publisher","first-page":"8295054","DOI":"10.1155\/2019\/8295054","volume":"2019","author":"R Bauersachs","year":"2019","unstructured":"Bauersachs R, Zeymer U, Bri\u00e8re JB, Marre C, Bowrin K, Huelsebeck M. Burden of coronary artery disease and peripheral artery disease: a literature review. Cardiovasc Ther. 2019;2019:8295054.","journal-title":"Cardiovasc Ther"},{"issue":"9","key":"12431_CR3","doi-asserted-by":"publisher","first-page":"610","DOI":"10.5812\/kowsar.20741804.2286","volume":"13","author":"M Ebrahimi","year":"2011","unstructured":"Ebrahimi M, Kazemi-Bajestani S, Ghayour-Mobarhan M, Ferns G. Coronary artery disease and its risk factors status in Iran: a review. Iran Red Crescent Med J. 2011;13(9):610.","journal-title":"Iran Red Crescent Med J"},{"issue":"3","key":"12431_CR4","first-page":"114","volume":"4","author":"S Soheilykhah","year":"2012","unstructured":"Soheilykhah S, Rashidi M, Dehghan F, Kiani G, Dara N, Souzani A, Rahimi-Saghand S. Prevalence of peripheral arterial disease in diabetic patients. Iranian J Diab Obes. 2012;4(3):114\u20139.","journal-title":"Iranian J Diab Obes"},{"issue":"5","key":"12431_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/13696998.2020.1715415","volume":"23","author":"C Emery","year":"2020","unstructured":"Emery C, Torreton E, Briere J-B, Evers T, Fagnani F. Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis. J Med Econ. 2020;23(5):513\u201320.","journal-title":"J Med Econ"},{"issue":"38","key":"12431_CR6","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.2174\/1381612825666190101100832","volume":"24","author":"DI Tsilimigras","year":"2018","unstructured":"Tsilimigras DI, Moris D, Karaolanis G, Kakkos SK, Filis K, Sigala F. Rivaroxaban versus clopidogrel for peripheral artery disease: a clinico-economic approach of the COMPASS trial. Curr Pharm Des. 2018;24(38):4516\u20137.","journal-title":"Curr Pharm Des"},{"issue":"8","key":"12431_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.cjca.2014.05.013","volume":"30","author":"GJ Mancini","year":"2014","unstructured":"Mancini GJ, Gosselin G, Chow B, Kostuk W, Stone J, Yvorchuk KJ, et al. Canadian cardiovascular society guidelines for the diagnosis and management of stable ischemic heart disease. Can J Cardiol. 2014;30(8):837\u201349.","journal-title":"Can J Cardiol"},{"key":"12431_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"T Cohnert","year":"2018","unstructured":"Cohnert T, Collet J-P, Czerny M. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763\u2013821.","journal-title":"Eur Heart J"},{"issue":"9678","key":"12431_CR9","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849\u201360.","journal-title":"Lancet"},{"issue":"03","key":"12431_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1160\/TH10-09-0601","volume":"105","author":"AG Turpie","year":"2011","unstructured":"Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Thromb Haemost. 2011;105(03):444\u201353.","journal-title":"Thromb Haemost"},{"issue":"26","key":"12431_CR11","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"E Investigators","year":"2010","unstructured":"Investigators E. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499\u2013510.","journal-title":"N Engl J Med"},{"issue":"10","key":"12431_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"issue":"14","key":"12431_CR13","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319\u201330.","journal-title":"N Engl J Med"},{"issue":"19","key":"12431_CR14","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791\u2013800.","journal-title":"N Engl J Med"},{"key":"12431_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/DDDT.S30342","volume":"6","author":"DH Fitchett","year":"2012","unstructured":"Fitchett DH. Potential role of rivaroxaban in patients with acute coronary syndrome. Drug Des Dev Ther. 2012;6:349.","journal-title":"Drug Des Dev Ther"},{"issue":"5","key":"12431_CR16","first-page":"184","volume":"13","author":"L Hernandez","year":"2020","unstructured":"Hernandez L, Shah A, Zhao Q, Milentijevic D, Kharat A. Economic implications of preventing major cardiovascular and limb events with rivaroxaban plus aspirin in patients with coronary or peripheral artery disease in the United States. American Health Drug Benefits. 2020;13(5):184.","journal-title":"American Health Drug Benefits"},{"issue":"8","key":"12431_CR17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1177\/2047487318817910","volume":"26","author":"E Zomer","year":"2019","unstructured":"Zomer E, Si S, Hird TR, Liew D, Owen AJ, Tonkin A, et al. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: an Australian healthcare perspective. Eur J Prev Cardiol. 2019;26(8):858\u201368.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"12431_CR18","first-page":"295","volume":"16","author":"E Zarepur","year":"2020","unstructured":"Zarepur E, Mohammadifard N, Mansourian M, Roohafza H, Sadeghi M, Khosravi A, et al. Rationale, design, and preliminary results of the Iran-premature coronary artery disease study (I-PAD): A multi-center case-control study of different Iranian ethnicities. ARYA Atheroscl. 2020;16(6):295.","journal-title":"ARYA Atheroscl"},{"issue":"7","key":"12431_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.119.039609","volume":"140","author":"KR Branch","year":"2019","unstructured":"Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK, et al. Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease: the COMPASS trial. Circulation. 2019;140(7):529\u201337.","journal-title":"Circulation"},{"issue":"21","key":"12431_CR20","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","volume":"382","author":"MP Bonaca","year":"2020","unstructured":"Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994\u20132004.","journal-title":"N Engl J Med"},{"issue":"10117","key":"12431_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","volume":"391","author":"SS Anand","year":"2018","unstructured":"Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219\u201329.","journal-title":"Lancet"},{"issue":"1","key":"12431_CR22","first-page":"38","volume":"9","author":"F Yari","year":"2022","unstructured":"Yari F, Agheli L, Sadeghi H, Faraji DS. Life expectancy forecast: implications for policy and economy in Iran. Health Manag Inform Sci. 2022;9(1):38\u201344.","journal-title":"Health Manag Inform Sci"},{"issue":"2","key":"12431_CR23","first-page":"191","volume":"25","author":"AH Mozayani","year":"2021","unstructured":"Mozayani AH, Sahabi B, Asadi M. Estimating social discount rate trend in Iran. Iranian Econ Rev. 2021;25(2):191\u2013203.","journal-title":"Iranian Econ Rev"},{"key":"12431_CR24","unstructured":"https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.PP.CD?locations=IR. I-GpcAf."},{"key":"12431_CR25","unstructured":"World Bank. PPP conversion factor, national currency to US dollars [Internet]. Washington, DC: World Bank; [cited 2025 Feb 16]. Available from: https:\/\/data.worldbank.org\/indicator\/PA.NUS.PPP."},{"key":"12431_CR26","unstructured":"Iranian Food and Drug Administration. National Food Information [Internet]. Tehran: Iranian Food and Drug Administration; [cited 2025 Feb 16]."},{"key":"12431_CR27","unstructured":"Tariff Committee for Medical Services. Tariff for medical services 1403 [Internet]. Tehran: Shahid Beheshti University of Medical Sciences; [cited 2025 Feb 16]. Available from: https:\/\/treatment.sbmu.ac.ir\/Tariff-for-medical-services-1403."},{"issue":"3","key":"12431_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10557-020-07059-w","volume":"35","author":"M-C Lee","year":"2021","unstructured":"Lee M-C, Liao C-T, Toh HS, Chou C-C, Chang W-T, Chen Z-C, et al. Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. Cardiovasc Drugs Ther. 2021;35(3):539\u201347.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"12431_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40261-021-01023-8","volume":"41","author":"P Ferrara","year":"2021","unstructured":"Ferrara P, Cortesi PA, Di Laura D, Maggioni AP, Mantovani LG. Cost-effectiveness analysis of rivaroxaban plus aspirin compared with aspirin alone in patients with coronary and peripheral artery diseases in Italy. Clin Drug Investig. 2021;41(5):459\u201368.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"12431_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","volume":"15","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, Force I-SMGRPT. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force-6. Value Health. 2012;15(6):835\u201342.","journal-title":"Value Health"},{"key":"12431_CR31","doi-asserted-by":"crossref","unstructured":"Dakin H, Devlin N, Feng Y, Rice N, O'neill P, Parkin D. The influence of cost\u2010effectiveness and other factors on nice decisions. Health economics. 2015;24(10):1256\u201371.","DOI":"10.1002\/hec.3086"},{"key":"12431_CR32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40258-021-00668-y","volume":"19","author":"S Prinja","year":"2021","unstructured":"Prinja S, Chugh Y, Rajsekar K, Muraleedharan V. National methodological guidelines to conduct budget impact analysis for health technology assessment in India. Appl Health Econ Health Policy. 2021;19:811\u201323.","journal-title":"Appl Health Econ Health Policy"},{"key":"12431_CR33","unstructured":"Shahjehan RD, Bhutta BS. Coronary artery disease. StatPearls: StatPearls Publishing; 2023."},{"issue":"3","key":"12431_CR34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jvn.2024.04.001","volume":"42","author":"A Rai","year":"2024","unstructured":"Rai A, Baridkazemi S, Sobhiyeh M, Amiri M, Ghorbani M, Shafiei S, Rahmanipour E. Prevalence and risk factors associated with coronary artery disease in Iranian patients with peripheral artery disease. J Vasc Nurs. 2024;42(3):154\u20138.","journal-title":"J Vasc Nurs"},{"key":"12431_CR35","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.2147\/IJGM.S383485","volume":"15","author":"Z Debasu","year":"2022","unstructured":"Debasu Z, Kedir HM, Tadesse TA. Comparison of aspirin and rivaroxaban plus aspirin in the management of stable coronary artery disease or peripheral artery disease: a systematic review of randomized controlled trials. Int J General Med. 2022;15:7201\u20138.","journal-title":"Int J General Med"},{"issue":"10117","key":"12431_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","volume":"391","author":"SJ Connolly","year":"2018","unstructured":"Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205\u201318.","journal-title":"Lancet"},{"key":"12431_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2018.06.091","volume":"270","author":"Z Ademi","year":"2018","unstructured":"Ademi Z, Zomer E, Tonkin A, Liew D. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: an Australian perspective. Int J Cardiol. 2018;270:54\u20139.","journal-title":"Int J Cardiol"},{"issue":"1","key":"12431_CR38","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1080\/13696998.2021.1997024","volume":"24","author":"J Spoorendonk","year":"2021","unstructured":"Spoorendonk J, Briere J-B, Bowrin K, Millier A, Coppens M, Tempelaar S, Verheggen B. Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands. J Med Econ. 2021;24(1):1231\u20139.","journal-title":"J Med Econ"},{"key":"12431_CR39","first-page":"j5058","volume":"359","author":"A Lamy","year":"2022","unstructured":"Lamy A, Eikelboom J, Tong W, Yuan F, Bangdiwala SI, Bosch J, et al. The cost-effectiveness of Rivaroxaban with or without aspirin in the COMPASS trial. European Heart J Qual Care Clin Outcomes. 2022;359:j5058.","journal-title":"European Heart J Qual Care Clin Outcomes"},{"key":"12431_CR40","doi-asserted-by":"publisher","first-page":"921387","DOI":"10.3389\/fphar.2022.921387","volume":"13","author":"T Feng","year":"2022","unstructured":"Feng T, Zheng Z, Gao S, Xu J, Cao P, Jia H, Yu X. Cost-effectiveness analysis of rivaroxaban in chinese patients with stable cardiovascular disease. Front Pharmacol. 2022;13:921387.","journal-title":"Front Pharmacol"},{"key":"12431_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12962-020-00241-9","volume":"18","author":"N Moradi","year":"2020","unstructured":"Moradi N, Woldemichael A, Malekian P, Rotvandi DM, Rezaei S. An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran. Cost Effect Resource Allocation. 2020;18:1\u20139.","journal-title":"Cost Effect Resource Allocation"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12431-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12431-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12431-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T02:23:56Z","timestamp":1740795836000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12431-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12431"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12431-3","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this work was achieved from Ethics Committee of the Shiraz University of Medical Sciences (ethic number: IR.SUMS.REC.1401.314). In this study, we did not use patient samples, so participant consent was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"326"}}